Dendreon Expects More Modest Provenge Sales

Dendreon Corp. (Nasdaq: DNDN) swung to a profit for the fourth quarter of 26 cents per share compared with a loss of 64 cents per share in the year ago period but warned of significant charges in the first quarter and forecast lower than expected sales of Provenge in the first quarter. Shares of the biotechnology company planed $2.91 to $11.95.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here

Portions of this content may be copy written by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. SmartReadMX and other related related technologies used to produce content for this service are covered by US Patents numbers 7,865,496, 7,856,390, and 7,716,116.